Team 10

Research Goal

The classical therapeutic scheme for neural cancers, such as Glioblastoma and Neuroblastoma, involved surgery followed with a combination of radio- and chemotherapies. However tumor location and acquired treatment resistance limit the efficacy of these treatments. Novel non-genotoxic therapeutic approaches in combination with actual treatments are currently being explored to improve their efficacy.

On this basis, the PETRY team explores key parameters involved in tumor aggressiveness and relapse, in particular tumor metabolic adaptation and tumor microenvironment cooption.

Our research program is organized around three main axis :
1) The tumor plasticity by deciphering the dynamic evolution of multiple tumor cell states, including molecular subtypes, tumor-stem cells and metabolic heterogeneity
2) The vascular microenvironment and its impact on tumor agressivity and relapse, in particular following radiotherapy/chemotherapy
3) The development of innovative immunotherapeutic strategies through antibody and T-cell engineering

photo equipe

Contact us

We are open to applications from highly motivated individuals.

François Paris, DR INSERM
francois.paris@univ-nantes.fr
Claire Pecqueur, DR CNRS
claire.pecqueur@univ-nantes.fr

Medias

Tumor plasticity

We have shown that GBM are characterized by diverses molecular, cellular and metabolic states, that evolve with time and treatments. We are interested in understanding this dynamic evolution of tumor cells, to subsequently exploit whereas preventing cell states transition or targeting tumor metabolic plasticity could be exploited to reduce GBM aggressiveness or to sensitize them to radio/chemotherapy. How radiation modulate cell state transition and metabolism are also key questions to answer before turning these potential vulnerabilities into therapeutic opportunity.

Vascular TME

Vascular dysfunction plays a key role in the enhancement of RT-induced tumor regression and normal tissue toxicity after RT. We recently define that irradiated endothelial cells are developing a different acute and late secretome. We are willing to understand their similarity and difference in the modulation of RT efficacy. Final goal of this project is to facilitate the development of new therapeutic strategies targeting tumor microenvironment to prevent the resistance and recurrence of tumors after RT, which is a major challenge to prolong patient survival

Innovant therapies

Since 2008, our team focuses on immunotherapeutic strategies targeting the O-acetylated form of GD2 (OAcGD2). Being a carbohydrate antigen, OAcGD2 possesses identical biochemical structures between species, allowing antigen cross-reactivity and is a T cell-independent antigen, an interesting characteristic in poorly immunogenic tumors. We have shown that OAcGD2 is highly expressed on all NB tumors, but, contrary to GD2, is not found on peripheral nerves, pituitary gland and human brain. We have developed the 8B6 anti-OAcGD2 chimeric antibody which display immunological antitumor activity (ADCC and CDC) similar to GD2 mAb in vitro and in vivo. Our recent work has also shown that adoptive transfer of allogeneic Vγ9Vδ2 T lymphocytes might be considered as an efficient immunotherapy, at least in GBM). The final goal of these projects is to establish the proof-of-concept of targeted immunotherapies in preclinical models of GBM, NB and MB in combination with RT, essential for its translation to phase I/II clinical trials.

Team Members

François Paris, DR INSERM
Claire Pecqueur, DR CNRS

Sophie Fougeray, MCU
Catherine Gratas, MCU-PH
Noémie Joalland, Post-doctorante
Yves Mathieu, ATER NU
Colin Niaudet, CR junior NEXT
Lisa Oliver, IR CHU
Christophe Olivier, MCU
Céline Salaud, MCU-PH
François Vallette, DR INSERM

Marine Devinat, IE CDD
Laetitia Durand, AI
Mylene Guérif, Tech CDD
Aline Perrin, Tech ICO

Hala Awada, Doctorante
Mélanie Laurent--Blond, Doctorante
Pierre Paris, Doctorant
Estrella Passerat de la Chapelle, Doctorante

Chercheurs associés
Dr. S. Faraj, PU-CHU
Dr. A. Lisbona, PH ICO
Dr. E. Rio, PH ICOt
Dr. C. Salaud, MCU-PH
Dr. E. Thébaud, PH ICO

Publications

Main Publications :

2024 :

Pauline Thomas, Pierre Paris, Claire Pecqueur. Arming Vd2 T cells with chimeric receptor to combat cancer. Accepted March 24 in Clinical Cancer Research
Pauline Thomas, Maëva Veerasamy, Marine Devinat, Elodie Guiet, Jocelyn Ollier, Pierre Paris, Natacha Entz-Werlé, Catherine Gratas, Béatrice Clémenceau, Stéphane Birklé, François Paris, Claire Pecqueur, Sophie Fougeray. Targeting pediatric High-Grade Gliomas with OAcGD2-CAR Vδ2 T cells. BIORXIV. doi: https://doi.org/10.1101/2023.11.17.567375.

2023 :

Awada H, Paris F, Pecqueur C. Exploiting radiation immunostimulatory effects to improve glioblastoma outcome. Neuro Oncol. 2023 Mar 14;25(3):433-446. doi: 10.1093/neuonc/noac239. PMID: 36239313; PMCID: PMC10013704.
Niaudet C, Jung B, Kuo A, Swendeman S, Bull E, Seno T, Crocker R, Fu Z, Smith LEH, Hla T. Therapeutic activation of endothelial sphingosine-1-phosphate receptor 1 by chaperone-bound S1P suppresses proliferative retinal neovascularization. EMBO Mol Med. 2023 May 8;15(5):e16645. doi: 10.15252/emmm.202216645. Epub 2023 Mar 13. PMID: 36912000 Free PMC article.
Rafia C, Loizeau C, Renoult O, Harly C, Pecqueur C, Joalland N, Scotet E. The antitumor activity of human Vγ9Vδ2 T cells is impaired by TGF-β through significant phenotype, transcriptomic and metabolic changes. Front Immunol. 2023 Jan 19;13:1066336. doi: 10.3389/fimmu.2022.1066336. PMID: 36741364; PMCID: PMC9893774.
Pu Y, Li L, Peng H, Liu L, Heymann D, Robert C, Vallette F, Shen S. Drug-tolerant persister cells in cancer: the cutting edges and future directions. Nat Rev Clin Oncol. 2023 Nov;20(11):799-813. doi: 10.1038/s41571-023-00815-5. Epub 2023 Sep 25. PMID: 37749382 Review.

2022 :

Ophélie Renoult, Catherine Gratas, Noémie Joalland, Mélanie Laurent--Blond, Hala Awada, Marine Bourgeois, Lisa Oliver, Sophie Chiavassa, Mikaël Croyal, François Paris, Claire Pecqueur. Pyruvate carboxylation identifies Glioblastoma Stem-like Cells opening new metabolic strategy to prevent tumor recurrence. BIORXIV. doi:https://doi.org/10.1101/2022.07.18.500427
Alzial G, Renoult O, Paris F, Gratas C, Clavreul A, Pecqueur C. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Oncogene. 2022 Jan;41(5):613-621. doi: 10.1038/s41388-021-02056-1. Epub 2021 Nov 11. PMID: 34764443; PMCID: PMC8799461.
Charlotte Degorre, Ophélie Renoult, Ann Christin Parplys, Hala Awada, Anne Clavreul, Manon Pietri, Lisa Oliver, Noemie Joalland, Michelle Ricoul, Catherine Gratas, François Vallette, Kirsten Borgmann, Laure Sabatier, Claire Pecqueur*, François Paris*. Mechanistic insights of radiation-induced endothelial senescence impelling glioblastoma genomic instability at relapse. BioRXIV doi: https://doi.org/10.1101/2021.12.13.472364.
Rabé M, Fonteneau L, Oliver L, Morales-Molina A, Jubelin C, Garcia-Castro J, Heymann D, Gratas C, Vallette FM. Cellular Heterogeneity and Cooperativity in Glioma Persister Cells Under Temozolomide Treatment. Front Cell Dev Biol. 2022 May 25;10:835273. doi: 10.3389/fcell.2022.835273. eCollection 2022. PMID: 35693929 Free PMC article.
Garnier D, Ratcliffe E, Briand J, Cartron PF, Oliver L, Vallette FM. The Activation of Mesenchymal Stem Cells by Glioblastoma Microvesicles Alters Their Exosomal Secretion of miR-100-5p, miR-9-5p and let-7d-5p. Biomedicines. 2022 Jan 6;10(1):112. doi: 10.3390/biomedicines10010112. PMID: 35052791 Free PMC article.
Lalier L, Vallette F, Manon S. Bcl-2 Family Members and the Mitochondrial Import Machineries: The Roads to Death. Biomolecules. 2022 Jan 19;12(2):162. doi: 10.3390/biom12020162. PMID: 35204663 Free PMC article. Review.
Jubelin C, Muñoz-Garcia J, Griscom L, Cochonneau D, Ollivier E, Heymann MF, Vallette FM, Oliver L, Heymann D. Three-dimensional in vitro culture models in oncology research. Cell Biosci. 2022 Sep 11;12(1):155. doi: 10.1186/s13578-022-00887-3. PMID: 36089610 Free PMC article. Review.

2021 :

Thomas P, Galopin N, Bonérandi E, Clémenceau B, Fougeray S, Birklé S. CAR T Cell Therapy's Potential for Pediatric Brain Tumors Cancers (Basel). 2021 Oct 29;13(21):5445. doi: 10.3390/cancers13215445. PMID: 34771608 Free PMC article. Review.
Alzial G, Renoult O, Paris F, Gratas C, Clavreul A, Pecqueur C. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Oncogene. 2022 Jan;41(5):613-621. doi: 10.1038/s41388-021-02056-1. Epub 2021 Nov 11. PMID: 34764443 Free PMC article. Review.
Lalier L, Mignard V, Joalland MP, Lanoé D, Cartron PF, Manon S, Vallette FM. TOM20-mediated transfer of Bcl2 from ER to MAM and mitochondria upon induction of apoptosis. Cell Death Dis. 2021 Feb 15;12(2):182. doi: 10.1038/s41419-021-03471-8. PMID: 33589622 Free PMC article.
Poczobutt JM, Mikosz AM, Poirier C, Beatman EL, Serban KA, Gally F, Cao D, McCubbrey AL, Cornell CF, Schweitzer KS, Berdyshev EV, Bronova IA, Paris F, Petrache I. Altered Macrophage Function Associated with Crystalline Lung Inflammation in Acid Sphingomyelinase Deficiency. Am J Respir Cell Mol Biol. 2021 May;64(5):629-640. doi: 10.1165/rcmb.2020-0229OC. PMID: 33662226 Free PMC article
Almeida L, Estrada-Rodriguez G, Oliver L, Peurichard D, Poulain A, Vallette F. Treatment-induced shrinking of tumour aggregates: a nonlinear volume-filling chemotactic approach J Math Biol. 2021 Aug 24;83(3):29. doi: 10.1007/s00285-021-01642-x. PMID: 34427771
Prasanna PG, Citrin DE, Hildesheim J, Ahmed MM, Venkatachalam S, Riscuta G, Xi D, Zheng G, Deursen JV, Goronzy J, Kron SJ, Anscher MS, Sharpless NE, Campisi J, Brown SL, Niedernhofer LJ, O'Loghlen A, Georgakilas AG, Paris F, Gius D, Gewirtz DA, Schmitt CA, Abazeed ME, Kirkland JL, Richmond A, Romesser PB, Lowe SW, Gil J, Mendonca MS, Burma S, Zhou D, Coleman CN. Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy. J Natl Cancer Inst. 2021 Oct 1;113(10):1285-1298. doi: 10.1093/jnci/djab064. PMID: 33792717 Free PMC article.
Foucault A, Ravalet N, Besombes J, Picou F, Gallay N, Babin L, Bourgeais J, Hamard S, Domenech J, Loyer P, Vallet N, Lejeune J, Gyan E, Béné MC, Vallette F, Olivier C, Hérault O. Low-Dose Pesticides Alter Primary Human Bone Marrow Mesenchymal Stem/Stromal Cells through ALDH2 Inhibition. Cancers (Basel). 2021 Nov 14;13(22):5699. doi: 10.3390/cancers13225699. PMID: 34830855 Free PMC article.
Olivier C, Oliver L, Lalier L, Vallette FM. Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress. Front Mol Biosci. 2021 Jan 27;7:620677. doi: 10.3389/fmolb.2020.620677. eCollection 2020. PMID: 33585565 Free PMC article. Review.
Bahri M, Kailayangiri S, Vermeulen S, Galopin N, Rossig C, Paris F, Fougeray S, Birklé S. SIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells. Cancer Immunol Immunother. 2022 Jan;71(1):71-83. doi: 10.1007/s00262-021-02968-7. Epub 2021 May 22. PMID: 34023958

2020 :

Garnier D, Renoult O, Alves-Guerra MC, Paris F, Pecqueur C. Glioblastoma Stem-Like Cells, Metabolic Strategy to Kill a Challenging Target. Front Oncol. 2019. 9:118.
Fleurence J, Bahri M, Fougeray S, Faraj S, Vermeulen S, Pinault E, Geraldo F, Oliver O, Véziers J, Marquet P, Rabé M, Gratas C, Vallette F, Pecqueur C, Paris F, Birklé S. Impairing Temozolomide Resistance Driven by Glioma Stem-Like Cells With Adjuvant Immunotherapy Targeting O-acetyl GD2 Ganglioside. Int. J. Cancer. 2020. 146 (2): 424-438
Rabé M, Dumont S, Álvarez-Arenas A, Janati H, Belmonte-Beitia J, Calvo GF, Thibault-Carpentier C, Séry Q, Chauvin C, Joalland N, Briand F, Blandin S, Scotet E, Pecqueur C, Clairambault J, Oliver L, Perez-Garcia V, Nadaradjane A, Cartron PF, Gratas C, Vallette FM. Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. Cell Death Dis. 2020. 11(1):19
Pecqueur C & F. Paris. When mitochondrial metabolism meets tumour cell radiobiology. ESTRO Newsletter Sept 2020
Oizel K, Yang C, Renoult O, Gautier F, Do QN, Joalland N, Gao X, Ko B, Vallette F, Ge WP, Paris F, DeBerardinis RJ, Pecqueur C. Glutamine uptake and utilization of human mesenchymal Glioblastoma in orthotopic mouse model. Cancer & Metabolism 2020; 8: 9. Published online 2020 Aug 10.
Ketteler J, Leonetti D, Veas Roy V, Estephan H, Wittka A, Maier P, Reis H, Herskind C, Jendrossek V, Paris F, Klein D. Caveolin 1 regulates the ASMase/ ceramide-mediated radiation-response of endothelial cells in the context of tumor-stroma-interactions. Cell Death Dis. 2020. Apr; 11(4): 228
Leonetti D, Estéphan H, Ripoche N, Dubois N, Aguesse A, Gouard S, Brossard L, Chiavassa S, Corre I, Pecqueur C, Neunlist M, Hadchity E, Gaugler MH, Mahé MM, Paris F. Secretion of acid sphingomyelinase and ceramide by endothelial cells contributes to radiation-induced intestinal toxicity. 2020. Cancer Res. 2020 Jun 15;80(12):2651-2662. doi: 10.1158/0008-5472.CAN-19-1527. Epub 2020 Apr 14.
Averbeck D, Candéias S, Chandna S , Foray N, Friedl AA, Haghdoost S, Jeggo PA, Lumniczky K, Paris F, Quintens R, Sabatier L. Establishing Mechanisms Affecting the Individual Response to Ionizing Radiation. Int J Radiat Biol. 2020. 1:1-27
Oliver L, Lalier L, Salaud C, Heymann D, Cartron PF, Vallette FM. Drug resistance in glioblastoma: are persisters the key to therapy? Cancer Drug Resist 2020 Aug 7;3(3):287-301: DOI: 10.20517/cdr.2020.29
Duforestel M, Briand J, Bougras-Cartron G, Heymann D, Frenel JS, Vallette FM, Cartron PF. Cell-free circulating epimarks in cancer monitoring. Epigenomics. 2020 Jan 9. doi: 10.2217/epi-2019-0170
Potiron V, Clément-Colmou K, Jouglar E, Pietri M, Chiavassa S, Delpon G, Paris F, Supiot S. Tumor Vasculature Remodeling by Radiation Therapy Increases Doxorubicin Distribution and Efficacy. Cancer Lett. 2020. 457: 1-9
Clément-Colmou K, Potiron V, Pietri M, Guillonneau M, Jouglar E, Chiavassa S, Delpon G, Paris F, Stéphane Supiot. Influence of Radiotherapy Fractionation Schedule on the Tumor Vascular Microenvironment in Prostate and Lung Cancer Models. Cancers. 2020 12 (1).
Dufresne S, Guéritat J, Chiavassa S, Noblet C, Assi M, Rioux-Leclercq N, Rannou-Bekono F, Lefeuvre-Orfila L, Paris F, Rébillard A. Exercise training improves radiotherapy efficiency in a murine model of prostate cancer. FASEB J 2020. Accepted. PMID 32043634
Mignard V, Dubois N, Lanoé D, Joalland MP, Oliver L, Pecqueur C, Heymann D, Paris F, Vallette FM, Lalier L. Sphingolipids Distribution at Mitochondria-Associated Membranes (MAM) Upon Induction of Apoptosis. 2020. J Lipid Res. 2020 Jul;61(7):1025-1037.
Salaud C, Alvarez-Arenas A, Geraldo F, Belmonte-Beitia J, Calvo GF, Gratas C, Pecqueur C, Garnier D, Pérez-Garcià V, Vallette FM, Oliver L. Mitochondria transfer from tumor-activated stromal cells (TASC) to primary Glioblastoma cells. Biochem Biophys Res Commun. 2020 Sep 14:S0006-291X(20)31699-5. doi: 10.1016/j.bbrc.2020.08.101.
Briand J, Garnier D, Nadaradjane A, Clément-Colmou K, Potiron V, Supiot S, Bougras-Cartron G, Frenel JS, Heymann D, Vallette FM, Cartron PF. Radiotherapy-induced overexpression of exosomal miRNA-378a-3p in cancer cells limits natural killer cells cytotoxicity. Epigenomics. 2020 Mar;12(5):397-408. doi: 10.2217/epi-2019-0193
Cheray M, Etcheverry A, Jacques C, Pacaud R, Bougras-Cartron G, Aubry M, Denoual F, Peterlongo P, Nadaradjane A, Briand J, Akcha F, Heymann D, Vallette FM, Mosser J, Ory B, Cartron PF. Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme. Mol Cancer. 2020 Feb 25;19(1):36. doi: 10.1186/s12943-020-01155-z
Briand J, Sérandour AA, Nadaradjane A, Bougras-Cartron G, Heymann D, Ory B, Vallette FM, Cartron PF. N6-Adenosine Methylation of miRNA-200b-3p Influences Its Functionality and Is a Theranostic Tool. Mol Ther Nucleic Acids. 2020 Aug 14;22:72-83. doi: 10.1016/j.omtn.2020.08.010
Pérez-García VM, Calvo GF, Bosque JJ, León-Triana O, Jiménez J, Pérez-Beteta J, Belmonte-Beitia J, Valiente M, Zhu L, García-Gómez P, Sánchez-Gómez P, Hernández-San Miguel E, Hortigüela R, Azimzade Y, Molina-García D, Martínez A, Acosta Rojas A, Ortiz de Mendivil A, Vallette FM, Schucht P, Albillo D, Pérez-Cano M, Murek M, Honguero Martínez AF, Jiménez Londoño GA, Arana E, García Vicente AM. Universal scaling laws rule explosive growth in human cancers. Nat Phys. 2020 Dec;16(12):1232-1237. doi: 10.1038/s41567-020-0978-6. Epub 2020 Aug 10. PMID: 33329756 Free PMC article.
Pariset E, Penninckx S, Kerbaul CD, Guiet E, Macha AL, Cekanaviciute E, Snijders AM, Mao JH, Paris F, Costes SV. 53BP1 Repair Kinetics for Prediction of In Vivo Radiation Susceptibility in 15 Mouse Strains. Radiat Res. 2020 Nov 10;194(5):485-499. doi: 10.1667/RADE-20-00122.1 PMID: 32991727
Guyon N, Garnier D, Briand J, Nadaradjane A, Bougras-Cartron G, Raimbourg J, Campone M, Heymann D, Vallette FM, Frenel JS, Cartron PF Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells. Cell Death Dis. 2020 Dec 11;11(12):1048. doi: 10.1038/s41419-020-03224-z. PMID: 33311449

2019 :

Leveque X, Hochane M, Geraldo F, Dumont S, Gratas C, Oliver L, Gaignier C, Trichet V, Layrolle P, Heymann D, Herault O, Vallette FM, Olivier C. Low-Dose Pesticide Mixture Induces Accelerated Mesenchymal Stem Cell Aging In Vitro. Stem Cells. 2019. 37(8):1083-1094.
Supiot S, Rousseau C, Dore M, Chèze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, Paris F, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D. Reoxygenation during radiotherapy in intermediate-risk prostate cancer. Radiother Oncol. 2019.133:16-19.
Sosa Marrero C, Acosta O, Castro M, Hernandez, Rioux-Leclercq N, Paris F, de Crevoisier R. Sensitivity analysis of an in silico model of tumor growth and radiation response. IEEE. 2019. Processing article. ISBI.
Briand J, Nadaradjane A, Bougras-Cartron G, Olivier C, Vallette FM, Cartron PF. Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation. Clinical Epigenetics. 2019
Duforestel M, Nadaradjane A, Bougras-Cartron G, Olivier C, Frenel JS, Vallette FM, Lelièvre S, Cartron PF. Glyphosate primes mammary cells for tumorigenesis by reprogramming the epigenome in a TET3-dependent manner. Frontiers in Genetics. 2019
Valès S, Bacola G, Biraud M, Touvron M, Bessard A, Geraldo F, Dougherty KA, Lashani S, Bossard C, Flamant M, Duchalais E, Marionneau-Lambot S, Oullier T, Oliver L, Neunlist M, Vallette FM, Van Landeghem L. Tumor cells hijack enteric glia to activate colon cancer stem cells and stimulate tumorigenesis. EBioMedicine. 2019 Nov;49:172-188. doi: 10.1016/j.ebiom.2019.09.045. Epub 2019 Oct 26.
Ginisty A, Oliver L, Arnault P, Vallette F, Benzakour O, Coronas V.. The vitamin K-dependent factor, protein S, regulates brain neural stem cell migration and phagocytic activities towards glioma cells. Eur J Pharmacol. 2019 Jul 15;855:30-39. doi: 10.1016/j.ejphar.2019.04.039. Epub 2019 Apr 24
Chauvin C, Joalland N, Perroteau J, Jarry U, Lafrance L, Willem C, Retière C, Oliver L, Gratas C, Gautreau-Rolland L, Saulquin X, Vallette FM, Vié H, Scotet E, Pecqueur C. NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells. Clin Cancer Res. 2019. 25(23):7218-7228
Aguilar E, Esteves P, Sancerni T, Lenoir V, Aparicio T, Bouillaud F, Dentin R, Prip-Buus C, Ricquier D, Pecqueur C, Guilmeau S, Alves-Guerra MC. UCP2 Deficiency Increases Colon Tumorigenesis by Promoting Lipid Synthesis and Depleting NADPH for Antioxidant Defenses. Cell Rep. 2019. 28(9):2306-2316
Bahri M, Fleurence J, Faraj S, Ben Mostefa Daho M, Fougeray S, Birklé S. Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation. J Vis Exp. 2019;(143).
Marin E, Bouchet-Delbos L, Renoult O, Louvet C, Nerriere-Daguin V, Managh AJ, Even A, Giraud M, Vu Manh TP, Aguesse A, Bériou G, Chiffoleau E, Alliot-Licht B, Prieur X, Croyal M, Hutchinson JA, Obermajer N, Geissler EK, Vanhove B, Blancho G, Dalod M, Josien R, Pecqueur C, Cuturi MC, Moreau A. Human Tolerogenic Dendritic Cells Regulate Immune Responses through Lactate Synthesis. Cell Metab. 2019. 30(6):1075-1090

2018 :

Kilens S, Meistermann D, Moreno D, Chariau C, Gaignerie A, Reignier A, Lelièvre Y, Casanova M, Vallot C, Nedellec S, Flippe L, Firmin J, Song J, Charpentier E, Lammers J, Donnart A, Marec N, Deb W, Bihouée A, Le Caignec C, Pecqueur C, Redon R, Barrière P, Bourdon J, Pasque V, Soumillon M, Mikkelsen TS, Rougeulle C, Fréour T, David L Parallel derivation of isogenic human primed and naive induced pluripotent stem cells. Nat Commun. 2018. 9(1):360
Jarry U, Joalland N, Chauvin C, Clemenceau B, Pecqueur C, Scotet E. Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts. J Vis Exp. 2018. (139):57870
Joalland N, Chauvin C, Oliver L, Vallette FM, Pecqueur C, Jarry U, Scotet E IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors. J Immunother. 2018. 41(5):224-231
Brown HK, Tellez-Gabriel M, Cartron PF, Vallette FM, Heymann MF, Heymann D. Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? Drug Discov Today. 2019 Mar;24(3):763-772. doi: 10.1016/j.drudis.2018.11.017. Epub 2018 Nov 26. Review.
Noblet C, Delpon G, Supiot S, Potiron V, Paris F, Chiavassa S. A new tissue segmentation method to calculate 3D dose in small animal radiation therapy. Radiat Oncol. 2018. 13(1):32
Vallette FM, Olivier C, Lézot F, Oliver L, Cochonneau D, Lalier L, Cartron PF, Heymann D. Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer.Biochem Pharmacol. 2019 Apr;162:169-176. doi: 10.1016/j.bcp.2018.11.004. Epub 2018 Nov 9. Review.
Nadaradjane A, Briand J, Bougras-Cartron G, Disdero V, Vallette FM, Frenel JS, Cartron PF. miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker. Mol Ther Nucleic Acids. 2018 Dec 7;13:642-650. PMID: 30497054.
Briand J, Nadaradjane A, Vallette FM, Cartron PF (2018) The TET2 Expression Level Correlates with a Short Relapse Time in Glioblastoma Multiforme. J Clin Epigenet 4:12. doi: 10.21767/2472-1158.100097
Chalopin A, Tellez-Gabriel M, Brown HK, Vallette F, Heymann MF, Gouin F, Heymann D.. Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy. J Bone Oncol. 2018 Jul 26;12:83-90. doi: 10.1016/j.jbo.2018.07.002. eCollection 2018 Sep
Supiot S, Rousseau C, Dore M, Cheze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, Paris F, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D. Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using 18F-fluoromisonidazole PET/CT: a pilot study. Oncotarget. 2018. 9(11):10005-10015.
Guipaud O, Jaillet C, Clément-Colmou K, François A, Supiot S, Milliat F. The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy. British Journal of Radiology (2018)

2017 :

Oizel K, Chauvin C, Oliver L, Gratas C, Geraldo F, Jarry U, Scotet E, Rabe M, Alves-Guerra MC, Teusan R, Gautier F, Loussouarn D, Compan V, Martinou JC, Vallette FM, Pecqueur C. Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity. Clin Cancer Res. 2017. 23(20):6292-6304
Fleurence J, Fougeray S, Bahri M, Cochonneau D, Clémenceau B, Paris F, Heczey A, Birklé S. Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy. J Immunol Res. 2017; 2017. 5604891.
Niaudet C, Bonnaud S, Guillonneau M, Gouard S, Gaugler MH, Dutoit S, Ripoche N, Dubois N, Trichet V, Corre I, Paris F. Plasma membrane reorganization links acid sphingomyelinase /ceramide to p38 MAPK pathways in endothelial cells apoptosis. Cell. Signal. 2017. ;33:10-21
Lafargue A, Degorre C, Corre I, Alves-Guerra MC, Gaugler MH, Vallette F, Pecqueur C, Paris F. Ionizing radiation induces long-term senescence in endothelial cells through mitochondrial respiratory complex II dysfunction and superoxide generation. Free Radic Biol Med. 2017. 108:750-759.
Corre I, Paris F, Houle F, Huot J. p38, a major pleiotropic pathway that transduces stress and metastatic signals in endothelial cells. Oncotarget. 2017. 8:55684-714
Faraj S, Bahri M, Fougeray S, El Roz A, Fleurence J, Véziers J, Leclair MD, Thébaud E, Paris F, Birklé S. Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside. Oncoimmunology. 2017. 7(1):e1373232.
Hochane M, Trichet V, Pecqueur C, Avril P, Oliver L, Denis J, Brion R, Amiaud J, Pineau A, Naveilhan P, Heymann D, Vallette FM, Olivier C. Low-Dose Pesticide Mixture Induces Senescence in Normal Mesenchymal Stem Cells (MSC) and Promotes Tumorigenic Phenotype in Premalignant MSC. Stem Cells. 2017. 35(3):800-811
Harford-Wright E, Andre-Gregoire G, Jacobs KA, Treps L, Le Gonidec S, Leclair HM, Gonzalez-Diest S, Roux Q, Guillonneau F, Loussouarn D, Oliver L, Vallette FM, Foufelle F, Valet P, Davenport AP, Glen RC, Bidere N, Gavard J. Pharmacological targeting of apelin impairs glioblastoma growth. Brain. 2017 Nov 1;140(11):2939-2954. doi: 10.1093/brain/awx253
Raimbourg J, Joalland MP, Cabart M, de Plater L, Bouquet F, Savina A, Decaudin D, Bennouna J, Vallette FM, Lalier L. Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib. Mol Cancer Ther. 2017 Aug;16(8):1634-1644. doi: 10.1158/1535-7163.MCT-17-0075. Epub 2017 May 18.
Alligand B, Le Breton M, Marquis D, Vallette F, Fleury F. Functional effects of diphosphomimetic mutations at cAbl-mediated phosphorylation sites on Rad51 recombinase activity. Biochimie. 2017 Aug;139:115-124. doi: 10.1016/j.biochi.2017.05.020. Epub 2017 May 29
Peyraga G, Lizee T, Gustin P, Clement-Colmou K, Di Bartolo C, Supiot S, Mahe MA, François S, Mege M. Treatment of cutaneous and/or soft tissue manisfestations of corticostreroids refractory graft versus host disease (cGVHD) by a total nodal irradiation (TNI). Clin Transplant. 2017 Apr;31(4)
Clement-Colmou K, Roualdes V, Martin SA, Josset S, Desal H, Campion L, Thillays F. Dynamic conformal arc radiosurgery for arteriovenous malformations : Outcome and influence of clinical and dosimetrical data. Radiother Oncol. 2017 May;123(2):251-256
Séry Q, Rabé M, Oliver L, Vallette FM, Gratas C. HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide. Biochem Biophys Res Commun. 2017. 493(4):1377-1383.
Pautu V, Leonetti D, Lepeltier E, Clere N, Passirani C. Nanomedicine as a potent strategy in melanoma tumor microenvironment. Pharmacological Research (2017)
Paul-Gilloteaux P, Potiron V, Delpon G, Supiot S, Chiavassa S, Paris F, Costes SV. Optimizing radiotherapy protocols using computer automata to model tumor cell death in function of oxygen diffusion processes. Sci Rep. 2017. 23;7(1):2280.